Agios Secures Global License for Cevidoplenib

Agios Secures Global License for Cevidoplenib
Cevidoplenib Advances Due to Strategic Partnership with Oscotec

Agios Pharmaceuticals has formed an exclusive worldwide license agreement for Cevidoplenib, a novel SYK inhibitor. The collaboration aims to bring this treatment to patients suffering from immune-mediated conditions such as immune thrombocytopenia. Speaking to stakeholders, CEO Brian Goff highlighted the drug’s potential to offer improved efficacy and safety for ITP patients. The deal is expected to set the stage for accelerated clinical development, positioning the company at the forefront of rare disease treatment.

The agreement includes a substantial upfront payment of $25 million for Oscotec, with additional milestone payments and tiered royalties anticipated. Agios anticipates maintaining stable operating expenses in 2026. With orphan drug designation from the FDA, Cevidoplenib is positioned as a promising new option in limited therapeutic areas. Industry analysts note the strategic move could enhance Agios’ rare hematology portfolio.

Cevidoplenib is designed to specifically target pathways involved in immune-driven disorders. It demonstrates clinically meaningful Phase 2 results, improving platelet counts while ensuring a favorable safety profile. Agios is targeting Phase 3 trials for ITP in the first half of 2028, following completion of CMC development.

Source link